Nouscom Announces First Patient Dosed in Phase 2 Randomized

BASEL, Switzerland, Nov. 15, 2022 /PRNewswire/ -- Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized immunotherapies, today announced the first patient

Related Keywords

Ankara , Turkey , Switzerland , Texas , United States , Eleanor Perkin , Prnewswire Nouscom , Rick Davis , Marwang Fakih , Sylvie Berrebi , Bristol Myers Squibb , Michaelj Overman , Marina Udier , Kostenloser Wertpapierhandel , Linkedin , University Of Texas Md Anderson Cancer Center , Department Of Gastrointestinal Medical Oncology , Janssen Research Development , Microsatellite Instable High , Principal Investigator , Gastrointestinal Medical Oncology , Cancer Center , Science Translational , Chief Executive Officer , Lynch Syndrome , Professor Marwan , Based Vaccine Promotes Neoantigen Specific , Science Translational Medicine , Great Ape Adenoviral , Modified Vaccinia Ankara , Lynch Syndrome Carriers , Myeloproliferative Neoplasms , Janssen Research , Nouscom , Nnounces , First , Patient , Hosed , Hase , Randomized , Trial , Yous , Shelf , Eoantigen , Dancer , Immunotherapy , Mmr , Thigh , Metastatic , Olorectal ,